US20030055026A1 - Formoterol/steroid bronchodilating compositions and methods of use thereof - Google Patents
Formoterol/steroid bronchodilating compositions and methods of use thereof Download PDFInfo
- Publication number
- US20030055026A1 US20030055026A1 US09/887,496 US88749601A US2003055026A1 US 20030055026 A1 US20030055026 A1 US 20030055026A1 US 88749601 A US88749601 A US 88749601A US 2003055026 A1 US2003055026 A1 US 2003055026A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- composition
- concentration
- buffer
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RWZAMDSZKGCHDB-UHFFFAOYSA-N [H]N(CC(O)C1=CC(NC=O)=C(O)C=C1)C(C)CC1=CC=C(C)C=C1 Chemical compound [H]N(CC(O)C1=CC(NC=O)=C(O)C=C1)C(C)CC1=CC=C(C)C=C1 RWZAMDSZKGCHDB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- compositions and methods are provided relating to treatment, prevention, or amelioration of one or more symptoms of broncho-constrictive disorders.
- the compositions and methods herein include formoterol, and/or a derivative thereof, and a steroid, and/or a derivative thereof.
- the compositions are propellant-free, sterile unit dose or multidose inhalation solutions intended for administration via nebulization.
- Bronchoconstrictive disorders affect millions worldwide. Such disorders include asthma (including bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness), chronic bronchitis and other chronic obstructive pulmonary diseases. Compounds having ⁇ 2 -adrenoreceptor agonist activity have been developed to treat these conditions.
- Such compounds include, but are not limited to, Albuterol (a 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol); Bambuterol (dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester); Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenylene ester); Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol); Isoproterenol (4-(1-hydroxy-2-((1-methyl-ethyl)amino)ethyl)-1,2-benzenediol); Trimetoquinol (1,2,3,4-tetrahydro
- prophylactic therapeutics for use in treatment of bronchoconstrictive disorders include steroidal anti-inflammatory agents such as beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcenolone acetonide, dexamethasone, tipredane, ciclesonid, mometasone, mometasone furoate (Asmanex® TwisthalerTM, Shering-Plough Corporation, Kenilworth, N.J.), RPR 106541, fluticasone, fluticasone propionate and budesonide. These agents can be formulated for inhalation therapy.
- BDP beclomethasone dipropionate
- BMP beclomethasone monopropionate
- flunisolide triamcenolone acetonide
- dexamethasone tipredane
- ciclesonid acetonide
- mometasone mometas
- compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided.
- the compositions provided herein are stable solutions of a bronchodilating agent, and/or a derivative thereof, and a prophylactic therapeutic agent, including, but not limited to, a steroid and/or a derivative thereof.
- the compositions are formulated in a pharmacologically suitable fluid that contains water and that are stable during long term storage.
- the compositions are suitable for direct administration to a subject in need thereof.
- Pharmacologically suitable fluids include, but are not limited to, polar fluids, including protic fluids.
- the compositions are aqueous solutions.
- compositions provided herein possess an estimated shelf-life of greater than 1, 2 or 3 months usage time at 25° C. and greater than or equal to 1, 2 or 3 years storage time at 5° C. In certain of these embodiments, using Arrhenius kinetics, >80% or >85% or >90% or >95% estimated bronchodilating agent remains after such storage. These compositions are particularly useful for administration via nebulization.
- the subject is a mammal. In other embodiments, the subject is a human.
- compositions provided herein are formulated to remain stable over a relatively long period of time.
- the compositions provided herein are stored between ⁇ 15° C. and 25C., or between 2° C. and 8° C. In one embodiment, the compositions are stored at 5° C.
- Albuterol ⁇ 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
- Bambuterol dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester
- Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenyleneester
- Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol);
- Isoproterenol (4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol); Trimetoquinol (1,2,3,
- Formoterol for use in the compositions and methods provided herein includes 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereoisomer thereof; and also includes the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
- Prophylactic therapeutics for use in the compositions and methods herein include steroidal anti-inflammatory agents, including, but not limited to, beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, rofleponide, mometasone, mometasone furoate (Asmanex® TwisthalerTM, Shering-Plough Corporation, Kenilworth, N.J.), RPR 106541, fluticasone or fluticasone propionate and budesonide, or derivatives thereof.
- the steroidal anti-inflammatory is fluticasone, fluticasone propionate, budesonide, or a derivative thereof.
- compositions are administered via nebulization.
- Administration of a nebulized aerosol is preferred over the use of dry powders for inhalation in certain subject populations, including pediatric and geriatric groups.
- compositions for use in the methods provided herein contain a pharmaceutically acceptable derivative of formoterol.
- compositions for use in the methods provided herein contain a pharmaceutically acceptable salt of formoterol.
- Pharmaceutically acceptable salts include, but are not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates and fumarates.
- the compositions for use in the methods provided herein contain formoterol fumarate or formoterol fumarate dihydrate.
- the compositions for use in the methods provided herein contain formoterol tartrate.
- compositions for use in the methods provided herein contain budesonide or fluticasone propionate.
- Compositions containing formoterol, budesonide and a fluoroalkane propellant are disclosed in U.S. Pat. No. 6,004,537.
- Compositions containing formoterol and budesonide for dry powder inhalation or metered dose inhalation are disclosed in U.S. Pat. Nos. 5,674,860 and 5,972,919. These references do not disclose the compositions provided herein that are formulated in a pharmacologically suitable fluid, as defined herein, that contains water and that are stable during long term storage.
- compositions provided herein.
- the compositions may be formulated separately or mixed in a single composition.
- the compositions contained in the combinations may be administered sequentially or intermittently.
- the compositions contained in the combinations can be mixed prior to use or can be formulated as a single composition.
- the combinations may further include a nebulizer.
- the combinations can be packaged as kits, which optionally contain other components, including instructions for use of the nebulizer and/or instructions for mixing the compositions if provided separately.
- any nebulizer is contemplated for use in the kits and methods provided herein.
- the nebulizers for use herein nebulize liquid formulations, including the compositions provided herein, containing no propellant.
- the nebulizer may produce the nebulized mist by any method known to those of skill in the art, including, but not limited to, compressed air, ultrasonic waves, or vibration.
- the nebulizer may further have an internal baffle. The internal baffle, together with the housing of the nebulizer, selectively removes large droplets from the mist by impaction and allows the droplets to return to the reservoir. The fine aerosol droplets thus produced are entrained into the lung by the inhaling air/oxygen.
- Methods for the treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders including, but not limited to, asthma, including, but not limited to, bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness; chronic bronchitis; and other chronic obstructive pulmonary diseases are provided.
- the methods involve administering an effective amount of a pharmaceutical composition provided herein to a subject in need of such treatment.
- Articles of manufacture containing packaging material, a composition provided herein, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, are also provided.
- formoterol refers to 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereoisomer thereof.
- formoterol also refers to the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
- formoterol fumarate refers to a salt of formoterol having the formula (formoterol).1 ⁇ 2 fumarate.
- Formoterol fumarate dihydrate refers to the dihydrate of formoterol fumarate.
- formoterol free base refers to the neutral, anhydrous form of formoterol.
- a composition contains, e.g., 59 ⁇ g/mL of formoterol free base means that the composition contains 59 ⁇ g/mL of neutral, anhydrous formoterol.
- Such compositions may be prepared using a derivative of formoterol.
- budesonide refers to (RS)-11 ⁇ , 16 ⁇ , 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butraldehyde.
- the term budesonide refers to the (R) isomer, the (S) isomer, and mixtures thereof.
- fluticasone refers to (6 ⁇ , 9 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-hydroxyandrosta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
- Fluticasone propionate refers to (6 ⁇ , 9 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
- an aerosol is liquid or particulate matter dispersed in air. Aerosols include dispersions of liquids, including aqueous and other solutions, and solids, including powders, in air.
- a nebulized solution refers to a solution that is dispersed in air to form an aerosol.
- a nebulized solution is a particular form of an aerosol.
- a nebulizer is an instrument that is capable of generating very fine liquid droplet for inhalation into the lung.
- the nebulizing liquid or solution is atomized into a mist of droplets with a broad size distribution by methods known to those of skill in the art, including, but not limited to, compressed air, ultrasonic waves, or a vibrating orifice.
- Nebulizers may further contain, eq., a baffle which, along with the housing of the instrument, selectively removes large droplets from the mist by impaction.
- the mist inhaled into the lung contains fine aerosol droplets.
- a pharmacologically suitable fluid is a solvent suitable for pharmaceutical use which is not a liquified propellant gas.
- exemplary pharmacologically suitable fluids include polar fluids, including protic fluids such as water.
- a combination refers to any association between two or among more items.
- fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.
- a mixture is a mutual incorporation of two or more substances, without chemical union, the physical characteristics of each of the components being retained.
- the stability of a composition refers to the length of time at a given temperature that greater than 80%, 85%, 90% or 95% of the initial amount of active ingredient, e.g., formoterol, is present in the composition.
- a composition that is stable for 30 days at 25° C. would have greater than 80%, 85%, 90% or 95% of the initial amount of active ingredient present in the composition at 30 days following storage at 25° C.
- pharmaceutically acceptable derivatives of a compound include salts, esters, enol ethers, enol esters, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs.
- salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and
- esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and heterocyclyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids.
- Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of formula C ⁇ C(OR) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl ar heterocyclyl.
- enol esters include, but are not limited to, derivatives of formula C ⁇ C(OC(O)R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl ar heterocyclyl.
- Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecule, preferably 1 to about 100, more preferably 1 to about 10, most preferably one to about 2, 3 or 4, solvent or water molecules.
- Formoterol salts and hydrates are used in certain embodiments herein.
- treatment means any manner in which one or more of the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating cancer.
- amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
- a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
- the pharmaceutically active compound is modified such that the active compound will be regenerated by metabolic processes.
- the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
- the compounds for use in the compositions and methods provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds for use in the compositions provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. Thus, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
- bronchoconstriction refers to a reduction in the caliber of a bronchus or bronchi.
- undesired and/or uncontrolled bronchoconstriction refers to bronchoconstriction that results in or from a pathological symptom or condition.
- Pathological conditions include, but are not limited to, asthma and chronic obstructive pulmonary disease (COPD).
- Pathological symptoms include, but are not limited to, asthma and COPD.
- a composition is stable during “long term storage” means that the composition is suitable for administration to a subject in need thereof when it has an estimated shelf-life of greater than 1, 2 or 3 months usage time at 25° C. and greater than or equal to 1, 2 or 3 years storage time at 5° C.
- Arrhenius kinetics >80% or >85% or >90% or >95% estimated bronchodilating agent remains after such storage.
- Formoterol (2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide) is derived from adrenaline and, as noted above, is used as a ⁇ 2 -stimulator in inhalation therapy of respiratory diseases, particularly for the treatment of bronchial asthma. It has been reported that in patients with reversible obstructive respiratory diseases, formoterol has a bronchodilatory effect. This effect has a relatively rapid onset (approximately 1-3 minutes) and a relatively long duration (greater than 12 hours). Formoterol inhibits the release of leukotrienes and other messenger substances involved with inflammation, such as histamines. In addition, formoterol may bring about a hyperglycaemic activity.
- formoterol has been formulated as a dry powder and administered via devices such as the Turbuhaler® and the Aerolizer®. See, e.g., Seberova et al. (2000) Respir. Med. 94(6):607-611; Lotvall et al. (1999) Can. Respir. J. 6(5):412-416; Campbell et al. (1999) Respir. Med. 93(4):236-244; Nightingale et al. (1999) Am. J. Respir. Crit. Care Med. 159(6):1786-1790; Lecaillon et al. (1999) Eur. J. Clin. Pharmacol. 55(2):131-138; Bartow et al.
- Formoterol is also available as a tablet and a dry syrup in certain areas of the world (e.g., Atock®, marcketed by Yamanouchi Pharmaceutical Co. Ltd., Japan). Formoterol formulations are also available in other areas (e.g., Europe and U.S.) for propellant-based metered dose inhalers and dry powder inhalers (e.g., Turbuhaler®, Aerolizer® and Foradil Aerolizer®). None of these formulations are water based. Sterile, stable, aqueous based inhalation solutions of formoterol for nebulization are not available, nor have they been reported.
- compositions containing formoterol in combination with other active ingredients have been disclosed. See, e.g., U.S. Pat. Nos. 5,668,110, 5,683,983, 5,677,280 and 5,654,276 (formoterol and IL-5 inhibitors), 6,136,603 (formoterol and antisense modulators of IL-5), U.S. Pat. No. 5,602,110 (formoterol and milrinone), U.S. Pat. No. 5,525,623 (formoterol and a tryptase inhibitor), U.S. Pat. Nos.
- compositions containing formoterol have been disclosed in U.S. Pat. Nos. 5,677,809, 6,126,919, 5,733,526, 6,071,971, 6,068,833, 5,795,564, 6,040,344, 6,041,777, 5,874,481, 5,965,622 and 6,161,536.
- U.S. Pat. No. 6,150,418 discloses a “liquid active substance concentrate” containing formoterol in the form of its free base or in the form of one of the pharmacologically acceptable salts or addition products (adducts) thereof as active substance.
- This “liquid active substance concentrate” is reported to be a concentrated (i.e., greater than 10 mg/mL, preferably 75 to 500 mg/mL) solution or suspension that is stable for a period of several months possibly up to several years without any deterioration in the pharmaceutical quality. This patent teaches that it is the high concentration that allows for the stability of the concentrate.
- the “liquid active substance concentrate” is not suitable for direct administration to a subject.
- U.S. Pat. No. 6,040,344 discloses an aqueous aerosol formulation of formoterol tartrate for use in a nebulizer. This patent states that the formulation disclosed therein is not attractive for long term storage.
- Budenoside and Fluticasone Propionate Budesonide, (RS)-11 ⁇ , 16 ⁇ , 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with butraldehyde, is an anti-inflammatory, synthetic corticosteroid.
- Fluticasone propionate, (6 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester is a synthetic fluorinated corticosteroid, and is known for topical dermatologic use.
- Topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
- corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of prostaglandins and leukotrienes by inhibiting the release of arachidonic acid.
- compositions containing a ⁇ 2 -adrenoreceptor agonist and a steroid for administration via nebulization are provided.
- the compositions are sterile filtered and filled in vials, including unit dose vials providing sterile unit dose formulations which are used in a nebulizer and suitably nebulized.
- Each unit dose vial is sterile and is suitably nebulized without contaminating other vials or the next dose.
- the bulk sterile formulation is sterilized by steam, gamma radiation or is prepared using sterile steroidal powder.
- the unit dose vials are formed in a form-fill-seal machine or by any other suitable method known to those of skill in the art.
- the vials may be made of plastic materials that are suitably used in these processes.
- plastic materials for preparing the unit dose vials include, but are not limited to, low density polyethylene, high density polyethylene, polypropylene and polyesters.
- the plastic material is low density polyethylene.
- the ⁇ 2 -adrenoreceptor agonist in formoterol or a pharmaceutically acceptable derivative thereof.
- the formoterol for use in the compositions provided herein is formoterol fumarate.
- Formoterol refers to 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereo-isomer thereof.
- formoterol also refers herein to the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
- the compositions contain, in addition to a steroidal anti-inflammatory agent, including, but not limited to, budesonide and fluticasone propionate, formoterol free base at a concentration of about 5 ⁇ g/mL to about 2 ⁇ g/mL. In other embodiments, the maximum concentration of formoterol free base in the compositions is 1.5 ⁇ g/mL. In further embodiments, the concentration of formoterol free base in the compositions is about 10 ⁇ g/mL to about 1mg/mL, or about 50 ⁇ g/mL to about 200 ⁇ g/mL.
- a steroidal anti-inflammatory agent including, but not limited to, budesonide and fluticasone propionate
- the compositions contain formoterol fumarate at a concentration of about 80 ⁇ g/mL up to about 175 to 200 ⁇ g/mL. In further embodiments, the compositions contain formoterol fumarate at a concentration of about 90 ⁇ g/mL up to about 125 to 150 ⁇ g/mL.
- the formoterol fumarate is formulated, in certain compositions provided herein, at a concentration of about 100 ⁇ g/mL.
- the formoterol fumarate is formulated, in other compositions provided herein, at a concentration of about 85 ⁇ g/mL or about 170 ⁇ g/mL.
- the formoterol fumarate is formulated for single dosage administration via nebulization at a concentration of about 100 ⁇ g/mL.
- the compositions contain formoterol free base at a concentration of about 40 to about 150 ⁇ g/mL, particularly about 59 or about 118 ⁇ g/mL.
- compositions provided herein further contain, in addition to a ⁇ 2 -adrenoreceptor agonist, including formoterol, a seroidal anti-inflammatory agent, including, but not limited to, budesonide or fluticasone propionate.
- a ⁇ 2 -adrenoreceptor agonist including formoterol
- a seroidal anti-inflammatory agent including, but not limited to, budesonide or fluticasone propionate.
- Budesonide is (RS)-11 ⁇ , 16 ⁇ , 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butraldehyde.
- Budesonide also refers to the (R) isomer, the (S) isomer, and mixtures thereof.
- Fluticasone propionate refers to (6 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
- the compositions contain budesonide or fluticasone propionate at a concentration of about 5 ⁇ g/mL to about 2 mg/mL. In another embodiment, the compositions contain budesonide at a concentration of about 75 ⁇ g/mL to about 500 ⁇ g/mL, or about 125 ⁇ g/mL to about 500 ⁇ g/mL. In certain embodiments, the compositions contain budesonide at a concentration of about 125 ⁇ g/mL or 250, ⁇ g/mL.
- compositions contain fluticasone propionate at a concentration of about 75 ⁇ g/mL to about 1000 ⁇ g/mL, or about 250 ⁇ g/mL to about 1000 ⁇ g/mL. In further embodiments, the compositions contain fluticasone propionate at a concentration of about 125 ⁇ g/mL or about 250 ⁇ g/mL.
- compositions are formulated as solutions or suspensions with a pharmacologically suitable fluid.
- Pharmacologically suitable fluids include, but are not limited to, polar solvents, including, but not limited to, compounds that contain hydroxyl groups or other polar groups.
- solvents include, but are not limited to, water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
- Polar solvents also include protic solvents, including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture thereof.
- protic solvents including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture thereof.
- particularly suitable salts are those which display no or only negligible pharmacological activity after administration.
- the compositions have a pH of about 2.0 to about 8.0.
- the particular pH of a given composition for long term storage provided herein may be determined empirically using standard stability assays well known to those of skill in the art (see, e.g., the Examples).
- the compositions have a pH of about 4.0 to about 6.0, or about 4.5 to about 5.5.
- the compositions are formulated at a pH of about 4, 4.4 or 4.6 up to about 5.5, 5.7 or 6.
- the pH is about 5.0. It has been found herein that the rate constant for decomposition of an aqueous solution of formoterol is dependent on pH.
- the rate constant (k obs ) at 60° C. at a pH of 3, 4, 5 and 7 is approximately 0.62, 0.11, 0.044 and 0.55 day 31 1 , respectively. Therefore, the decomposition of formoterol in aqueous solution at 60° C. at a buffer concentration of 5 mM and an ionic strength of 0.05 is slowest at a pH of about 5.0.
- the solubility of formoterol in aqueous solution has been found herein to be dependent on pH.
- the aqueous solubility of formoterol at ambient temperature is approximately 2.2 mg/mL.
- the aqueous solubility of formoterol at ambient temperature is approximately 3 mg/mL, while at a pH of about 3, the aqueous solubility of formoterol at ambient temperature is about 4.8 mg/mL.
- the solubility of formoterol in pure water, for example, high performance liquid chromatography (HPLC) water, at ambient temperature is approximately 2 mg/mL.
- compositions further contain a buffer, including, but not limited to, citric acid/phosphate, acetate, barbital, borate, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, Mcllvaine, phosphate, Prideaux-Ward, succinate, citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES (2-(N-morpholino)ethanesulfonic acid), BIS-TRIS (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane), ADA (N-(2-acetamido)-2-iminodiacetic acid), ACES (N-(carbamoylmethyl)-2-aminoethanesulfonaic acid), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxy
- the buffer is citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer. In another embodiment, the buffer is a citrate buffer (citric acid/sodium citrate).
- the buffer concentration has been found herein to affect the stability of the composition. Buffer concentrations for use herein include from about 0 or 0.01 mM to about 150 mM, or about 1 mM to about 20 mM. In one embodiment, the buffer concentration is about 5 mM. In another embodiment, the buffer concentration is about 1 mM to about 50 mM, or about 20 mM. The kinetic-pH profile of formoterol is dependent on buffer concentration.
- the ionic strength of the compositions provided herein also has been found herein to affect the stability of the composition.
- Ionic strengths of the compositions provided herein are from about 0 to about 0.4, or from about 0.05 to about 0.16.
- Compositions having a lower ionic strength exhibit improved stability over formulations having higher ionic strength.
- the rate constant of decomposition was essentially the same at ionic strength 0.05 to 0.1, but increased to some extent at ionic strength of 0.2.
- the particular ionic strength of a given composition for long term storage provided herein may be determined empirically using standard stability assays well known to those of skill in the art (see, e.g., the Examples).
- tonicity adjusting agents may be added to provide the desired ionic strength.
- Tonicity adjusting agents for use herein include those which display no or only negligible pharmacological activity after administration. Both inorganic and organic tonicity adjusting agents may be used in the compositions provided herein.
- Tonicity adjusting agents include, but are not limited to, ammonium carbonate, ammonium chloride, ammonium lactate, ammonium nitrate, ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium tartrate, boric acid, calcium chloride, calcium disodium edetate, calcium gluconate, calcium lactate, citric acid, dextrose, diethanolamine, dimethylsulfoxide, edetate disodium, edetate trisodium monohydrate, fluorescein sodium, fructose, galactose, glycerin, lactic acid, lactose, magnesium chloride, magnesium sulfate, mannitol, polyethylene glycol, potassium acetate, potassium chlorate, potassium chloride, potassium iodide, potassium nitrate, potassium phosphate, potassium sulfate, proplyene glycol, silver nitrate, sodium acetate, sodium bicarbonate, sodium biphosphate,
- the tonicity adjusting agent is sodium chloride, which is present at a concentration of from about 0 mg/mL to about 10, 15 or 20 mg/mL.
- the compositions contain sodium chloride at a concentration of from about 0 mg/mL to about 7.5 mg/mL.
- the compositions contain sodium chloride at a concentration of 0 mg/mL, 1.5 mg/mL, 6.8 mg/mL or 7.5 mg/mL.
- the pharmacologically suitable fluid is aqueous saline.
- compositions stored at a lower temperature exhibit improved stability over formulations stored at higher temperatures.
- the estimated shelf-life of formoterol in the compositions provided herein is significantly greater than that reported for known formoterol compositions.
- the estimated shelf-life of formoterol in the compositions provided herein is about 6.2 years at 5° C. and about 7.5 months at 25° C.
- the estimated formoterol concentrations in the compositions provided herein as a function of storage time at 5° C and usage time at 25° C. was determined. It is estimated that greater than 90% of the initial formoterol present in the composition remains after 3 months of usage time at 25° C. and 3 years of storage time at 5° C. as well as after 0.5 months of usage time at 25° C. and 1 year of storage time at 5° C.
- compositions provided herein are prepared containing formoterol fumarate at a nominal concentration of 0.1 mg/mL at the indicated pH and citric acid/phosphate buffer concentrations.
- the solutions were stored at 60° C.
- formoterol is relatively more stable at a pH from about 4 to about 5, and is also more stable at lower buffer concentration.
- compositions provided herein also may include excipients and additives.
- the particular excipient or additive for use in the compositions for long term storage provided herein may be determined empirically using methods well known to those of skill in the art (see, e.g., the Examples).
- Excipients and additives are any pharmacologically suitable and therapeutically useful substance which is not an active substance. Excipients and additives generally have no pharmacological activity, or at least no undesirable pharmacological activity.
- the excipients and additives include, but are not limited to, surfactants, stabilizers, complexing agents, antioxidants, or preservatives which prolong the duration of use of the finished pharmaceutical formulation, flavorings, vitamins, or other additives known in the art.
- Complexing agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt, citric acid, nitrilotriacetic acid and the salts thereof.
- the complexing agent is EDTA.
- the complexing agent is sodium edetate.
- the compositions contain sodium edetate at a concentration of about 0.05 mg/mL to about 0.5 mg/mL, or about 0.1 mg/mL to about 0.2 mg/mL.
- Preservatives include, but are not limited to, those that protect the solution from contamination with pathogenic particles, including benzalkonium chloride or benzoic acid, or benzoates such as sodium benzoate.
- Antioxidants include, but are not limited to, vitamins, provitamins, ascorbic acid, vitamin E or salts or esters thereof.
- the compositions contain vitamin E TPGS (d- ⁇ -tocopheryl polyethylene glycol 1000 succinate).
- vitamin E TPGS is present at a concentration of about 0 mg/mL to about 100 mg/mL, or about 5 mg/mL to about 50 mg/mL.
- the compositions contain vitamin E TPGS at a concentration of 10 mg/mL, 20 mg/mL, 30 mg/mL or 50 mg/mL.
- compositions provided herein also may include a cosolvent, which increases the solubility of additives or the active ingredient(s).
- a cosolvent which increases the solubility of additives or the active ingredient(s).
- the particular cosolvent for use in the compositions for long term storage provided herein may be determined empirically using methods well known to those of skill in the art (see, eq., the Examples).
- Cosolvents for use herein include, but are not limited to, hydroxylated solvents or other polar solvents, such as alcohols such as isopropyl alcohol, glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, and polyoxyethylene alcohols.
- the compositions contain a glycol.
- the compositions contain propylene glycol and/or polyethylene glycol, including polyethylene glycol 400.
- the glycol is present at a concentration of 5 about 0 mg/mL to about 100 mg/mL, or about 5 mg/mL to about 50 mg/mL.
- the compositions contain propylene glycol at a concentration of 17 mg/mL or 20 mg/mL.
- the compositions contain polyethylene glycol 400 at a concentration of 10 mg/mL, 20 mg/mL, 30 mg/mL or 50 mg/mL.
- compositions provided herein may also contain one or more emulsifiers.
- Emulsifiers for use herein include, but are not limited to, polyoxyetheylene sorbitan fatty esters or polysorbates, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; lecithins; alginic acid; sodium alginate; potassium alginate; ammonium alginate; calcium alginate; propane-1,2-diol alginate; agar; carrageenan; locust bean gum;
- the emulsifier(s) is (are) a polyoxyetheylene sorbitan fatty ester or polysorbate, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan mono-oleate; or sorbitan monopalmitate.
- the emulsifier(s) is (are) polysorbate 80, sorbitan monolaruate or polyoxyethylene (20) sorbitan nmonolaurate.
- Formoterol may be prepared according to the method disclosed in U.S. Pat. No. 3,994,974. Briefly, 4-benzyloxy-3-nitro- ⁇ -bromoacetophenone is reacted with N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amine to form the a-aminoacetophenone.
- This compound was subjected to the following series of reactions: (i) reduction of the ketone with sodium borohydride; (ii) reduction of the nitro group with aqueous hydrochloric acid and iron powder; (iii) amine formulation with acetic anhydride and formic acid; and (iv) catalytic reduction over 10% palladium on carbon to afford formoterol free base. Crystallization of the 1 ⁇ 2 fumarate salt from ethanol provides (formoterol).1 ⁇ 2 fumarate.
- reaction of optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy- ⁇ -methyl-N-(phenylmethyl)benzeneethanamine, followed by debenzylation affords the desired enantiomer of formoterol.
- Debenzylation may be accomplished by reduction with hydrogen gas in the presence of a noble metal catalyst, such as palladium on carbon.
- the required optically pure 4-benzyloxy-3-formamidostyrene oxide may be prepared from 4-benzyloxy-3-nitro- ⁇ -bromoacetophenone by (i) reduction with vorane in the presence of an optically pure aminoindanol, (ii) hydrogenation over platinum oxide catalyst, (iii) formulation with formic acid and acetic anhydride, and (iv) epoxide formation in the presence of potassium carbonate.
- the required optically pure 4-methoxy- ⁇ -methyl-N-(phenylmethyl)-benzeneethanamine may be prepared from 4-methoxyphenylacetone by (i) reductive amination with benzylamine in the presence of hydrogen and a platinum catalyst, and (ii) crystallization of the desired optically pure amine from the resulting racemic mixture as its mandelic acid salt.
- Budesonide may be synthesized by the procedure disclosed in U.S. Pat. No. 3,929,768. Briefly, reaction of triamcinolon with propionaldehyde and catalyic perchloric acid in dry dioxane at ambient temperature provides, following chromatography on hydroxy-propylated, cross-linked dextran gel, budesonide.
- Fluticasone propionate may be synthesized by the procedure disclosed in U.S. Pat. No. 4,335,121. Briefly, the corresponding carbothioic acid is prepared from the carboxylic acid precursor by reaction with dimethylthiocarbamoyl chloride in the presence of triethylamine. Reaction with bromochloromethane and sodium hydrogen carbonate in dimethylacetamide affords the corresponding S-chloromethyl carbothioate. This compound is treated with sodium iodide in acetone to give the corresponding S-iodomethyl carbothioate. Fluoride substitution of the iodo group is accomplished by reaction with silver fluoride in acetonitrile to afford the desired compound.
- compositions provided herein are prepared by procedures well known to those of skill in the art.
- a solution formulations may be prepared by the procedure of EXAMPLE 1. Briefly, polyethylene glycol 400 and/or propolyene glycol, and a preservative, such as vitamin E TPGS, are mixed at about 42° C. until a homogeneous solution forms. The temperature is lowered and the steroidal anti-inflammatory agent is added. In a second vessel, formoterol fumarate dihydrate and the remaining ingredients are dissolved in approximately 70% water. The two solutions are mixed and the resulting solution is diluted with water to the desired volume.
- Suspension formulations are prepared by the procedure of EXAMPLE 2. Briefly, all ingredients other than the steroidal anti-inflammatory agent and formoterol fumarate dihydrate are dissolved in about 40% water with mixing. The steroidal anti-inflammatory agent, which is micronized, is dispersed in the above mixture with high speed homogenization. Formoterol fumarate dihydrate is dissolved in 50% water and added to the steroidal suspension with mixing until a uniform suspension forms.
- compositions provided herein are used for treating, preventing, or ameliorating one or more symptoms of a bronchoconstrictive disorders in a subject.
- the method includes administering to a subject an effective amount of a composition containing a ⁇ 2 -adrenoreceptor agonist, including, but not limited to, formoterol, and a steroidal anti-inflammatory agent, including, but not limited to, budesonide and fluticasone propionate, whereby the disease or disorder is treated or prevented, or one or more symptoms are ameliorated.
- the subject treated is, in certain embodiments, a mammal. In certain of these embodiments, the mammal is a human.
- the method provided herein includes oral administration of a composition provided herein.
- the composition is directly administered to a subject in need of such treatment via nebulization without dilution or other modification of the composition prior to administration.
- the methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders further include administering one or more of (a), (b) or (c) as follows: (a) a ⁇ 2 -adrenoreceptor agonist; (b) a dopamine (D 2 ) receptor agonist; or (c) an anti-cholinergic agent; simultaneously with, prior to or subsequent to the composition provided herein.
- ⁇ 2 -Adrenoreceptor agonists for use in combination with the compositions provided herein include, but are not limited to, Albuterol ( ⁇ 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol); Bambuterol (dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester); Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenylene ester); Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol); Isoproterenol (4-(1-hydroxy-2-( (1-methylethyl)amino)ethyl)
- Dopamine (D 2 ) receptor agonists include, but are not limited to, Apomorphine ((r)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol); Bromocriptine ((5′ ⁇ )-2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′, 18-trione); Cabergoline ((8 ⁇ )-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)ergoline-8-carboxamide); Lisuride (N′-((8 ⁇ )-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea); Pergolide ((8 ⁇ )-8-((methylthio)methyl)-6-propyler
- Anticholinergic agents for use herein include, but are not limited to, ipratropium bromide, oxitropium bromide, atropine methyl nitrate, atropine sulfate, ipratropium, belladonna extract, scopolamine, scopolamine methobromide, homatropine methobromide, hyoscyamine, isopriopramide, orphenadrine, benzalkonium chloride, tiotropium bromide and glycopyrronium bromide.
- the compositions contain an anticholinergic agent, such as ipratropium bromide or tiotropium bromide, at a concentration of about 5 ⁇ g/mL to about 5 mg/mL, or about 50 ⁇ g/mL to about 200 ⁇ g/mL.
- the compositions for use in the methods herein contain an anticholinergic agent, including ipratropium bromide and tiotropium bromide, at a concentration of about 83, ⁇ g/mL or about 167 ⁇ g/mL.
- IL-5 inhibitors such as those disclosed in U.S. Pat. Nos. 5,668,110, 5,683,983, 5,677,280 and 5,654,276; antisense modulators of IL-5 such as those disclosed in U.S. Pat. No. 6,136,603; milrinone (1,6-dihydro-2-methyl-6-oxo-[3,4′-bipyridine]-5-carbonitrile); milrinone lactate; tryptase inhibitors such as those disclosed in U.S. Pat. No. 5,525,623; tachykinin receptor antagonists such as those disclosed in U.S. Pat. Nos.
- leukotriene receptor antagonists such as montelukast sodium (Singular®, R-(E)1-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]-propyl]thiolmethyl]cyclopropaneacetic acid, monosodium salt), 5-lypoxygenase inhibitors such as zileuton (Zyflo®, Abbott Laboratories, Abbott Park, Ill.), and anti-IgE antibodies such as Xolair® (recombinant humanized anti-IgE monoclonal antibody (CGP 51901; IGE 025A; rhuMAb-E25), Genentech, Inc.).
- the bronchoconstrictive disorder to be treated, prevented, or whose one or more symptoms are to be ameliorated is associated with asthma, including, but not limited to, bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness; and, particularly in embodiments where an anticholinergic agent is used, other chronic obstructive pulmonary diseases (COPDs), including, but not limited to, chronic bronchitis, emphysema, and associated cor pulmonale (heart disease secondary to disease of the lungs and respiratory system) with pulmonary hypertension, right ventricular hypertrophy and right heart failure.
- COPD chronic obstructive pulmonary diseases
- COPD chronic obstructive pulmonary diseases
- compositions provided herein are intended for administration to a subject in need of such treatment via nebulization.
- Nebulizers that nebulize liquid formulations containing no propellant are suitable for use with the compositions provided herein.
- Nebulizers are available from, e.g., Pari GmbH (Starnberg, Germany), DeVilbiss Healthcare (Heston, Middlesex, UK), Healthdyne, Vital Signs, Baxter, Allied Health Care, Invacare, Hudson, Siemens, Aerogen, Omron, Bremed, AirSep, Luminscope, Medisana, Mountain Medical, Aerosol Medical Ltd. (Colchester, Essex, UK), AFP Medical (Rugby, Warwickshire, UK), Bard Ltd.
- Nebulizers for use herein include, but are not limited to, jet nebulizers (optionally sold with compressors), ultrasonic nebulizers, and others.
- Exemplary jet nebulizers for use herein include Pari LC plus/ProNeb, Pari LC plus/ProNeb Turbo, Pari LC plus/Dura Neb 1000 & 2000, Pari LC plus/Walkhaler, Pari LC plus/Pari Master, Pari LC star, Omron CompAir XL Portable Nebulizer System (NE-C18 and JETAir Disposable nebulizer), Omron CompAir Elite Compressor Nebulizer System (NE-C21 and Elite Air Reusable Nebulizer), Pari LC Plus or Pari LC Star nebulizer with Proneb Ultra compressor, Pulmo-aide, Pulmo-aide LT, Pulmo-aide traveler, Invacare Passport, Inspiration Healthdyne 626, Pulmo-Neb Traver
- Exemplary ultrasonic nebulizers for use herein include MicroAir, UltraAir, CompAir, Pulmosonic, Scout, 5003 Ultrasonic Neb, 5110 Ultrasonic Neb, 5004 Desk Ultrasonic Nebulizer, Mystique Ultrasonic, Siemens Ultra Nebulizer 145, Luminscope's Ultrasonic Nebulizer, Medisana Ultrasonic Nebulizer, Microstat Ultrasonic Nebulizer, and MABISMist Hand Held Ultrasonic Nebulizer.
- nebulizers for use herein include 5000 Electromagnetic Neb, AeronebTM Partable Nebulizer System, AerodoseTM Inhaler, 5001 Electromagnetic Neb 5002, Rotary Piston Neb, Lumineb I Piston Nebulizer 5500, and AeroEclipse Breath Actuated Nebulizer.
- compositions provided herein may be packaged as articles of manufacture containing packaging material, a composition provided herein, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.
- the articles of manufacture provided herein contain packaging materials.
- Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252.
- Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
- compositions are packaged with a nebulizer for direct administration of the composition to a subject in need thereof.
- Polyethylene glycol 400 and/or propylene glycol and vitamin E TPGS were mixed in a stainless steel container with heating at about 42° C. until a homogeneous liquied formed. While maintaining the liquid phase, the temperature was lowered and the steroid active ingredient, e.g., budesonide or fluticasone propionate, was added. The nixing was contiued untila all of the drug substance had dissolved. In another container all other ingredients, including formoterol fumarate dihydrate, were mixed with about 70% water until a clear solution formed. The two solutions were mixed together until a homogeneous clear solution formed. The volume was made up with water and the solution was mixed to give the desired composition.
- the steroid active ingredient e.g., budesonide or fluticasone propionate
- Fluticasone propionate/Formoterol solution formulations Concentration Ingredient Low strength High strength Formoterol fumarate 85 ⁇ g/mL 170 ⁇ g/mL dihydrate Fluticasone 125 ⁇ g/mL 250 ⁇ g/mL propionate Vitamin E TPGS 30 mg/mL 50 mg/mL Either: Propylene glycol 17 mg/mL 20 mg/mL or Polyethylene glycol 30 mg/mL 50 mg/mL 400 Citrate buffer 5 mM 5 mM Sodium Chloride 1.5 mg/mL 0 mg/mL Water q.s. q.s.
- Budesonide/Formoterol suspension formulations Ingredient Concentration Formoterol fumarate dihydrate 5-2000 ⁇ g/mL or 50-200 ⁇ g/mL Budesonide 125-500 ⁇ g/mL Disodium edetate 0.1-0.2 mg/mL Polysorbate 80 0.2-0.3 mg/mL Sodium chloride 5-10 mg/mL Citrate buffer 1-20 mM Water q.s.
- Fluticasone propionate/Formoterol suspension formulations Ingredient Concentration Formoterol fumarate dihydrate 5-2000 ⁇ g/mL or 50-200 ⁇ g/mL Fluticasone propionate micronized 250-1000 ⁇ g/mL Sorbitan monolaurate 0.05-0.2 mg/mL Polyoxyethylene 20 sorbitan 0.1-0.3 mg/mL monolaurate Sodium chloride 5-10 mg/mL Citrate buffer 1-20 mM Water q.s.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/887,496 US20030055026A1 (en) | 2001-04-17 | 2001-06-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
ES02719098.2T ES2572973T3 (es) | 2001-04-17 | 2002-03-01 | Composiciones que contienen formoterol y un esteroide para administración a los pulmones |
CA2444535A CA2444535C (en) | 2001-04-17 | 2002-03-01 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
AU2002250199A AU2002250199B2 (en) | 2001-04-17 | 2002-03-01 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
PCT/US2002/006252 WO2002083113A2 (en) | 2001-04-17 | 2002-03-01 | Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization |
JP2002580917A JP4580145B2 (ja) | 2001-04-17 | 2002-03-01 | フォルモテロール/ステロイド性気管支拡張組成物およびその使用方法 |
PT2719098T PT1385494T (pt) | 2001-04-17 | 2002-03-01 | Composições que contêm formoterol e um esteróide para administração aos pulmões |
SI200231075A SI1385494T1 (sl) | 2001-04-17 | 2002-03-01 | Sestavki, ki vsebujejo formoterol in steroid, za dovajanje v pljuča |
EP02719098.2A EP1385494B1 (en) | 2001-04-17 | 2002-03-01 | Compositions containing formoterol and a steroid for delivery into the lungs |
US10/145,978 US20020183293A1 (en) | 2001-04-17 | 2002-05-13 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
HK04104465.4A HK1061523A1 (zh) | 2001-04-17 | 2004-06-19 | 用於經噴霧遞送至肺的含有福莫特羅和類固醇的組合物 |
JP2009149871A JP2009235089A (ja) | 2001-04-17 | 2009-06-24 | フォルモテロール/ステロイド性気管支拡張組成物およびその使用方法 |
US12/625,328 US8623851B2 (en) | 2001-04-17 | 2009-11-24 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/692,095 US20100120734A1 (en) | 2001-04-17 | 2010-01-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US13/052,792 US8716348B2 (en) | 2001-04-17 | 2011-03-21 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US14/142,178 US9597396B2 (en) | 2001-04-17 | 2013-12-27 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28460701P | 2001-04-17 | 2001-04-17 | |
US09/887,496 US20030055026A1 (en) | 2001-04-17 | 2001-06-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/145,978 Division US20020183293A1 (en) | 2001-04-17 | 2002-05-13 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/692,095 Continuation US20100120734A1 (en) | 2001-04-17 | 2010-01-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030055026A1 true US20030055026A1 (en) | 2003-03-20 |
Family
ID=26962701
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/887,496 Abandoned US20030055026A1 (en) | 2001-04-17 | 2001-06-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US10/145,978 Abandoned US20020183293A1 (en) | 2001-04-17 | 2002-05-13 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/625,328 Expired - Lifetime US8623851B2 (en) | 2001-04-17 | 2009-11-24 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/692,095 Abandoned US20100120734A1 (en) | 2001-04-17 | 2010-01-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US13/052,792 Expired - Fee Related US8716348B2 (en) | 2001-04-17 | 2011-03-21 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US14/142,178 Expired - Lifetime US9597396B2 (en) | 2001-04-17 | 2013-12-27 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/145,978 Abandoned US20020183293A1 (en) | 2001-04-17 | 2002-05-13 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/625,328 Expired - Lifetime US8623851B2 (en) | 2001-04-17 | 2009-11-24 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US12/692,095 Abandoned US20100120734A1 (en) | 2001-04-17 | 2010-01-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US13/052,792 Expired - Fee Related US8716348B2 (en) | 2001-04-17 | 2011-03-21 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US14/142,178 Expired - Lifetime US9597396B2 (en) | 2001-04-17 | 2013-12-27 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
Country Status (10)
Country | Link |
---|---|
US (6) | US20030055026A1 (zh) |
EP (1) | EP1385494B1 (zh) |
JP (2) | JP4580145B2 (zh) |
AU (1) | AU2002250199B2 (zh) |
CA (1) | CA2444535C (zh) |
ES (1) | ES2572973T3 (zh) |
HK (1) | HK1061523A1 (zh) |
PT (1) | PT1385494T (zh) |
SI (1) | SI1385494T1 (zh) |
WO (1) | WO2002083113A2 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050009923A1 (en) * | 2003-07-10 | 2005-01-13 | Banerjee Partha S. | Bronchodilating beta-agonist compositions and methods |
US20050059643A1 (en) * | 2003-08-05 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a steroid and a betamimetic |
US20050244339A1 (en) * | 2003-10-15 | 2005-11-03 | Pari Gmbh | Pharmaceutical aerosol composition |
EP1604657A1 (en) * | 2004-05-31 | 2005-12-14 | Italchimici SpA | Pharmaceutical formulation of a stable Formoterol-containing solution for use in inhalation therapy and method of preparing it |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
US20070207091A1 (en) * | 2006-03-01 | 2007-09-06 | Mcaffer Ian G C | Nebulizer Formulation |
WO2007140285A3 (en) * | 2006-05-26 | 2008-02-14 | Dey L P | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
US20100069342A1 (en) * | 2001-04-17 | 2010-03-18 | Dey, L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US20120082626A1 (en) * | 2009-06-16 | 2012-04-05 | Wen Tan | Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders |
EP2749280A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and formoterol |
US20150125553A1 (en) * | 2003-07-09 | 2015-05-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Use of nitrite salts for the treatment of cardiovascular conditions |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
GB0204829D0 (en) * | 2002-03-01 | 2002-04-17 | Glaxo Group Ltd | A fluid dispensing device |
NZ538493A (en) * | 2002-08-29 | 2007-10-26 | Cipla Ltd | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
ES2312844T3 (es) * | 2002-12-12 | 2009-03-01 | Nycomed Gmbh | Medicamento de combinacion de r, r-formoterol y ciclesonida. |
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
GB0315889D0 (en) * | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
AU2011235943B2 (en) * | 2003-12-31 | 2014-06-26 | Cydex Pharmaceuticals, Inc | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
BRPI0418386A (pt) * | 2003-12-31 | 2007-05-22 | Cydex Inc | formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
WO2005082413A2 (en) * | 2004-02-27 | 2005-09-09 | Altana Pharma Ag | Ciclesonide and glycopyrronium combination |
AU2005231479C1 (en) * | 2004-04-05 | 2012-03-15 | Sunovion Pharmaceuticals Inc. | (R,R)-formoterol in combination with other pharmacological agents |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
EP2397034A1 (en) | 2005-07-14 | 2011-12-21 | Lithera, Inc. | Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment |
JP2009503014A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療におけるジヒドロプテリジノン |
US20080319079A1 (en) * | 2005-11-23 | 2008-12-25 | Feanny Stephen J | Method for Administering Formoterol Using a Nebulizer |
EP1971345A2 (en) * | 2005-12-20 | 2008-09-24 | Tika Läkemedel AB | Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197487A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an increased lung deposition |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
ES2389231T3 (es) * | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
GB0612748D0 (en) * | 2006-06-27 | 2006-08-09 | Univ College London Hospitals | Treatment and/or prevention of inflammatory lung disease |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
WO2008048770A1 (en) * | 2006-10-17 | 2008-04-24 | Lipothera, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
WO2008102128A2 (en) * | 2007-02-19 | 2008-08-28 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
US7999741B2 (en) * | 2007-12-04 | 2011-08-16 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene using precision location |
US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
AU2010258751A1 (en) * | 2009-06-09 | 2012-02-02 | Sunovion Respiratory Development Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
JP5717329B2 (ja) | 2009-10-09 | 2015-05-13 | キヤノン株式会社 | 固体撮像装置及びその製造方法 |
US20110224176A1 (en) * | 2010-01-15 | 2011-09-15 | Lithera, Inc. | Lyophilized Cake Formulations |
US10179139B2 (en) | 2010-10-12 | 2019-01-15 | Cipla Limited | Pharmaceutical composition |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
EA201270784A1 (ru) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
ES2758446T3 (es) | 2012-01-23 | 2020-05-05 | Sage Therapeutics Inc | Formulaciones de esteroides neuroactivos que comprenden un complejo de alopregnanolona y sulfobutil éter beta-ciclodextrina |
IN2014MN02133A (zh) | 2012-04-11 | 2015-10-09 | Cipla Ltd | |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
CA3017172C (en) | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN105748447A (zh) * | 2016-03-08 | 2016-07-13 | 上海现代药物制剂工程研究中心有限公司 | 布地奈德和福莫特罗雾化吸入混悬液及其制备方法 |
MX2023001201A (es) | 2020-07-31 | 2023-05-03 | Chemo Res S L | Terapia combinada para la administracion por inhalacion. |
WO2022217029A1 (en) * | 2021-04-09 | 2022-10-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
US5556964A (en) * | 1989-10-02 | 1996-09-17 | Aktiebolaget Astra | Process for the manufacture of budesonide |
US5637620A (en) * | 1993-08-27 | 1997-06-10 | Astra Aktiebolag | Micro formoterol particles |
US5674860A (en) * | 1991-12-18 | 1997-10-07 | Astra Aktiebolag | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US6027714A (en) * | 1997-01-20 | 2000-02-22 | Astra Aktiebolag | Formulation for inhalation |
US6199607B1 (en) * | 1997-01-20 | 2001-03-13 | Astra Aktiebolag | Formulation for inhalation |
US6291445B1 (en) * | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
US20020042404A1 (en) * | 1997-09-19 | 2002-04-11 | Astra Aktiebolag, A Swedish Corporation | Use for budesonide and formoterol |
US20020103260A1 (en) * | 1999-02-18 | 2002-08-01 | Clarke Jeremy Guy | Combinations of formoterol and fluticasone proppionate for asthma |
US6448296B2 (en) * | 1997-05-14 | 2002-09-10 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension with good redispersibility |
US20020151598A1 (en) * | 2001-04-17 | 2002-10-17 | Banerjee Partha S. | Bronchodilating compositions and methods |
US20020183293A1 (en) * | 2001-04-17 | 2002-12-05 | Banerjee Partha S. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US20030124063A1 (en) * | 2001-10-26 | 2003-07-03 | Imtiaz Chaudry | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
US6632842B2 (en) * | 2001-10-26 | 2003-10-14 | Dey, L.P. | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US6686346B2 (en) * | 1996-12-05 | 2004-02-03 | Astra Aktiebolag | Formulation |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
US20040110845A1 (en) * | 2002-12-06 | 2004-06-10 | Ramana Malladi | Stabilized albuterol compositions and method of preparation thereof |
US6814593B2 (en) * | 2001-08-21 | 2004-11-09 | Samsung Electronics Co., Ltd. | Portable computer having a common connector coupled to a wireless antenna and a modem connector |
US20050009923A1 (en) * | 2003-07-10 | 2005-01-13 | Banerjee Partha S. | Bronchodilating beta-agonist compositions and methods |
US7070800B2 (en) * | 2000-10-12 | 2006-07-04 | Boehringer Ingelheim Pharma Kg | Inhalable powder containing tiotropium |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
DE2366625C2 (zh) | 1972-02-05 | 1988-06-09 | Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp | |
SE378109B (zh) * | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3994976A (en) * | 1974-07-08 | 1976-11-30 | The Dow Chemical Company | Substituted phenylthioamidines |
BE887518A (fr) * | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US5052558A (en) * | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) * | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
GB8825892D0 (en) | 1988-11-04 | 1988-12-07 | Fisons Plc | Pharmaceutical composition |
US5290815A (en) * | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
ATE175801T1 (de) * | 1990-09-18 | 1999-01-15 | Rodime Plc | Digitale servosteuerung für ein plattenlaufwerk |
US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
JP3280974B2 (ja) | 1991-12-12 | 2002-05-13 | グラクソ、グループ、リミテッド | 医 薬 |
US5323907A (en) * | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5275212A (en) * | 1993-02-24 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Aerosol filling method |
US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
US5602110A (en) * | 1994-08-31 | 1997-02-11 | Case Western Reserve University | Method and composition for treating cystic fibrosis |
SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
DE19541689A1 (de) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
GB9425160D0 (en) | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
EE9700138A (et) | 1994-12-22 | 1997-12-15 | Astra Aktiebolag | Aerosoolravimvormid |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
US5733526A (en) * | 1995-12-14 | 1998-03-31 | Alliance Pharmaceutical Corp. | Hydrocarbon oil/fluorochemical preparations and methods of use |
GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
SE9603669D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
US5929094A (en) * | 1996-10-25 | 1999-07-27 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
GB9625843D0 (en) * | 1996-12-12 | 1997-01-29 | Merck & Co Inc | Phenyl spiroethercycloalkyl tachykinn receptor antagonists |
US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
JP2001511160A (ja) | 1997-02-05 | 2001-08-07 | ヤゴ リサーチ アクチェンゲゼルシャフト | 医学用エアゾール配合物 |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US6503537B2 (en) * | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
PT1393721E (pt) | 1997-03-20 | 2009-02-02 | Schering Corp | Forma de dosagem de aglomerados de pó |
BR9810452A (pt) | 1997-06-27 | 2000-09-05 | Astra Ab | Nova combinação de medicamentos contra asma |
US20010044584A1 (en) * | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
US6161536A (en) * | 1997-10-08 | 2000-12-19 | Sepracor Inc. | Dosage form for aerosol administration |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
WO1999036095A1 (en) | 1998-01-13 | 1999-07-22 | Astrazeneca Uk Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY |
WO1999040939A1 (en) | 1998-02-10 | 1999-08-19 | Cangene Corporation | Method for the prevention and treatment of a type i hypersensitivity disorder |
GB9806462D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
KR20010043820A (ko) | 1998-05-27 | 2001-05-25 | 유로셀띠끄 소시에떼 아노님 | 치밀하게 컴팩트된 고체약물스톡을 포함하는 약물전달시스템 |
CZ300910B6 (cs) | 1998-06-18 | 2009-09-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostredek |
US5965622A (en) * | 1998-06-23 | 1999-10-12 | Sepracor Inc. | Desformoterol and process for its preparation |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
ES2234266T3 (es) | 1998-07-24 | 2005-06-16 | Jago Research Ag | Formulaciones medicas para aerosoles. |
WO2000007567A1 (de) | 1998-08-04 | 2000-02-17 | Jago Research Ag | Medizinische aerosolformulierungen |
DE19835346A1 (de) | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
US6136294C1 (en) | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
DE19847970A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähige Wirkstoff-Formulierung |
ES2178479T3 (es) * | 1998-10-17 | 2002-12-16 | Boehringer Ingelheim Pharma | Concentrado de principio activo con formoterol, apto para el almacenamiento. |
DE19847968A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
US6235725B1 (en) * | 1998-10-30 | 2001-05-22 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for the prevention of tolerance to medications |
PT1131059E (pt) | 1998-11-13 | 2003-07-31 | Jago Res Ag | Po seco para inalacao |
SE9804003D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | A method of producing drug particles |
SE9804001D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
US6161535A (en) * | 1999-09-27 | 2000-12-19 | Carrier Corporation | Method and apparatus for preventing cold spot corrosion in induced-draft gas-fired furnaces |
DE19947235A1 (de) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
SE9903995D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US6369115B1 (en) * | 2000-03-20 | 2002-04-09 | Dura Pharmaceuticals, Inc. | Stabilized powder formulations |
WO2001078735A1 (en) | 2000-04-13 | 2001-10-25 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
GB0009591D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
MXPA02011414A (es) | 2000-05-22 | 2003-06-06 | Chiesi Farma Spa | Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis. |
GB0016876D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
WO2002007672A2 (en) | 2000-07-19 | 2002-01-31 | Aeropharm Technology, Inc. | A medicinal aerosol formulation |
SE516555C2 (sv) | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
FI20002177A0 (fi) | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
PL199420B1 (pl) | 2000-10-09 | 2008-09-30 | 3M Innovative Properties Co | Medyczne preparaty aerozolowe |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
AU2002226986A1 (en) | 2000-12-01 | 2002-06-11 | Rheologics, Inc. | In vivo delivery methods and compositions |
GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
SE0004750D0 (sv) | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
EP1343550B1 (en) | 2000-12-22 | 2017-11-22 | Glaxo Group Limited | Metered dose inhaler for salmeterol xinafoate |
CA2436535A1 (en) | 2001-01-31 | 2002-08-08 | Prizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
CZ20031902A3 (cs) | 2001-01-31 | 2004-07-14 | Pfizer Products Inc. | Etherové deriváty užitečné jako inhibitory isozymů PDE4 |
DE60203652T2 (de) | 2001-01-31 | 2005-09-08 | Pfizer Products Inc., Groton | Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme |
HUP0401305A2 (hu) | 2001-01-31 | 2004-10-28 | Pfizer Products Inc. | Tiazolil-, oxazolil-, pirrolil- és imidazolil-savamid-származékok, mint PDE4 izozimek inhibitorai és az ezeket tartalmazó gyógyszerkészítmények |
DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
BR0207062A (pt) | 2001-02-06 | 2004-10-05 | Innovata Biomed Ltd | Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal |
ITMI20010428A1 (it) | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
NZ531792A (en) | 2001-09-18 | 2006-02-24 | Nycomed Danmark Aps | Compositions for treatment of common cold |
GB0129395D0 (en) | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
-
2001
- 2001-06-22 US US09/887,496 patent/US20030055026A1/en not_active Abandoned
-
2002
- 2002-03-01 CA CA2444535A patent/CA2444535C/en not_active Expired - Lifetime
- 2002-03-01 WO PCT/US2002/006252 patent/WO2002083113A2/en active IP Right Grant
- 2002-03-01 SI SI200231075A patent/SI1385494T1/sl unknown
- 2002-03-01 EP EP02719098.2A patent/EP1385494B1/en not_active Expired - Lifetime
- 2002-03-01 ES ES02719098.2T patent/ES2572973T3/es not_active Expired - Lifetime
- 2002-03-01 JP JP2002580917A patent/JP4580145B2/ja not_active Expired - Lifetime
- 2002-03-01 PT PT2719098T patent/PT1385494T/pt unknown
- 2002-03-01 AU AU2002250199A patent/AU2002250199B2/en not_active Expired
- 2002-05-13 US US10/145,978 patent/US20020183293A1/en not_active Abandoned
-
2004
- 2004-06-19 HK HK04104465.4A patent/HK1061523A1/zh not_active IP Right Cessation
-
2009
- 2009-06-24 JP JP2009149871A patent/JP2009235089A/ja not_active Withdrawn
- 2009-11-24 US US12/625,328 patent/US8623851B2/en not_active Expired - Lifetime
-
2010
- 2010-01-22 US US12/692,095 patent/US20100120734A1/en not_active Abandoned
-
2011
- 2011-03-21 US US13/052,792 patent/US8716348B2/en not_active Expired - Fee Related
-
2013
- 2013-12-27 US US14/142,178 patent/US9597396B2/en not_active Expired - Lifetime
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5556964A (en) * | 1989-10-02 | 1996-09-17 | Aktiebolaget Astra | Process for the manufacture of budesonide |
US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
US5674860A (en) * | 1991-12-18 | 1997-10-07 | Astra Aktiebolag | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
US5637620A (en) * | 1993-08-27 | 1997-06-10 | Astra Aktiebolag | Micro formoterol particles |
US6291445B1 (en) * | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
US6686346B2 (en) * | 1996-12-05 | 2004-02-03 | Astra Aktiebolag | Formulation |
US6199607B1 (en) * | 1997-01-20 | 2001-03-13 | Astra Aktiebolag | Formulation for inhalation |
US6027714A (en) * | 1997-01-20 | 2000-02-22 | Astra Aktiebolag | Formulation for inhalation |
US6448296B2 (en) * | 1997-05-14 | 2002-09-10 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension with good redispersibility |
US20020042404A1 (en) * | 1997-09-19 | 2002-04-11 | Astra Aktiebolag, A Swedish Corporation | Use for budesonide and formoterol |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US20020103260A1 (en) * | 1999-02-18 | 2002-08-01 | Clarke Jeremy Guy | Combinations of formoterol and fluticasone proppionate for asthma |
US7070800B2 (en) * | 2000-10-12 | 2006-07-04 | Boehringer Ingelheim Pharma Kg | Inhalable powder containing tiotropium |
US20020183293A1 (en) * | 2001-04-17 | 2002-12-05 | Banerjee Partha S. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20020151598A1 (en) * | 2001-04-17 | 2002-10-17 | Banerjee Partha S. | Bronchodilating compositions and methods |
US6814593B2 (en) * | 2001-08-21 | 2004-11-09 | Samsung Electronics Co., Ltd. | Portable computer having a common connector coupled to a wireless antenna and a modem connector |
US6632842B2 (en) * | 2001-10-26 | 2003-10-14 | Dey, L.P. | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US20030124063A1 (en) * | 2001-10-26 | 2003-07-03 | Imtiaz Chaudry | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US6702997B2 (en) * | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
US20040110845A1 (en) * | 2002-12-06 | 2004-06-10 | Ramana Malladi | Stabilized albuterol compositions and method of preparation thereof |
US20050009923A1 (en) * | 2003-07-10 | 2005-01-13 | Banerjee Partha S. | Bronchodilating beta-agonist compositions and methods |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100069342A1 (en) * | 2001-04-17 | 2010-03-18 | Dey, L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US9597396B2 (en) | 2001-04-17 | 2017-03-21 | Mylan Specialty Lp | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US8716348B2 (en) | 2001-04-17 | 2014-05-06 | Dey Pharma, L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US8623851B2 (en) | 2001-04-17 | 2014-01-07 | Mylan Specialty L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US20100120734A1 (en) * | 2001-04-17 | 2010-05-13 | Dey, L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US9700578B2 (en) * | 2003-07-09 | 2017-07-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US9675637B2 (en) | 2003-07-09 | 2017-06-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US20150125553A1 (en) * | 2003-07-09 | 2015-05-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Use of nitrite salts for the treatment of cardiovascular conditions |
US7541385B2 (en) | 2003-07-10 | 2009-06-02 | Chaudry Imtiaz A | Bronchodilating β-agonist compositions and methods |
US8623922B2 (en) | 2003-07-10 | 2014-01-07 | Dey Pharma, L.P. | Bronchodilating Beta-agonist compositions and methods |
US20070166240A1 (en) * | 2003-07-10 | 2007-07-19 | Dey, L.P. | Bronchodilating beta-agonist compositions and methods |
US20070166235A1 (en) * | 2003-07-10 | 2007-07-19 | Dey, L.P. | Bronchodilating beta-agonist compositions and methods |
US9730890B2 (en) | 2003-07-10 | 2017-08-15 | Mylan Pharmaceuticals, Inc. | Bronchodilating beta-agonist compositions and methods |
WO2005007142A2 (en) * | 2003-07-10 | 2005-01-27 | Dey L.P. | Liquid compositions comprising formoterol |
US7348362B2 (en) | 2003-07-10 | 2008-03-25 | Dey, L.P. | Bronchodilating β-agonist compositions and methods |
US7462645B2 (en) | 2003-07-10 | 2008-12-09 | Jpmorgan Chase Bank, N.A. | Bronchodilating beta-agonist compositions and methods |
US7465756B2 (en) | 2003-07-10 | 2008-12-16 | Jpmorgan Chase Bank, N.A. | Bronchodilating beta-agonist compositions and methods |
US7473710B2 (en) | 2003-07-10 | 2009-01-06 | Jpmorgan Chase Bank, N.A. | Bronchodilating beta-agonist compositions and methods |
US20050009923A1 (en) * | 2003-07-10 | 2005-01-13 | Banerjee Partha S. | Bronchodilating beta-agonist compositions and methods |
US20070160541A1 (en) * | 2003-07-10 | 2007-07-12 | Dey, L.P. | Bronchodilating beta-agonist compositions and methods |
WO2005007142A3 (en) * | 2003-07-10 | 2005-03-03 | Dey L P | Liquid compositions comprising formoterol |
US20070166236A1 (en) * | 2003-07-10 | 2007-07-19 | Dey, L.P. | Bronchodilating beta-agonist compositions and methods |
US8114912B2 (en) | 2003-07-10 | 2012-02-14 | Mylan Pharmaceuticals, Inc. | Bronchodilating β-agonist compositions and methods |
US20100240761A1 (en) * | 2003-07-10 | 2010-09-23 | Dey, L.P. | Bronchodilating beta-agonist compositions and methods |
US20050059643A1 (en) * | 2003-08-05 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a steroid and a betamimetic |
US7758886B2 (en) | 2003-10-15 | 2010-07-20 | Pari Gmbh | Pharmaceutical aerosol composition |
US20050244339A1 (en) * | 2003-10-15 | 2005-11-03 | Pari Gmbh | Pharmaceutical aerosol composition |
EP1604657A1 (en) * | 2004-05-31 | 2005-12-14 | Italchimici SpA | Pharmaceutical formulation of a stable Formoterol-containing solution for use in inhalation therapy and method of preparing it |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
WO2006108556A3 (en) * | 2005-04-15 | 2007-05-03 | Pari Gmbh | Pharmaceutical aerosol composition |
US20070207091A1 (en) * | 2006-03-01 | 2007-09-06 | Mcaffer Ian G C | Nebulizer Formulation |
US20100143375A1 (en) * | 2006-05-26 | 2010-06-10 | Dey, L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
WO2007140285A3 (en) * | 2006-05-26 | 2008-02-14 | Dey L P | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
US20120082626A1 (en) * | 2009-06-16 | 2012-04-05 | Wen Tan | Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders |
CN102448309A (zh) * | 2009-06-16 | 2012-05-09 | 谭文 | 左旋(r)班布特罗在制备治疗呼吸性疾病的吸入性药物制剂和药物组合中的应用 |
EP2749280A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and formoterol |
Also Published As
Publication number | Publication date |
---|---|
ES2572973T3 (es) | 2016-06-03 |
US9597396B2 (en) | 2017-03-21 |
JP2005512944A (ja) | 2005-05-12 |
US8623851B2 (en) | 2014-01-07 |
EP1385494B1 (en) | 2016-05-11 |
HK1061523A1 (zh) | 2004-09-24 |
WO2002083113A3 (en) | 2003-03-20 |
US20100069342A1 (en) | 2010-03-18 |
CA2444535C (en) | 2010-07-13 |
US8716348B2 (en) | 2014-05-06 |
JP4580145B2 (ja) | 2010-11-10 |
JP2009235089A (ja) | 2009-10-15 |
US20100120734A1 (en) | 2010-05-13 |
US20110166202A1 (en) | 2011-07-07 |
US20140171398A1 (en) | 2014-06-19 |
CA2444535A1 (en) | 2002-10-24 |
EP1385494A2 (en) | 2004-02-04 |
PT1385494T (pt) | 2016-08-17 |
US20020183293A1 (en) | 2002-12-05 |
SI1385494T1 (sl) | 2016-09-30 |
AU2002250199B2 (en) | 2007-07-26 |
WO2002083113A2 (en) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9597396B2 (en) | Formoterol/steroid bronchodilating compositions and methods of use thereof | |
US6667344B2 (en) | Bronchodilating compositions and methods | |
US7465756B2 (en) | Bronchodilating beta-agonist compositions and methods | |
AU2002250199A1 (en) | Formoterol/steroid bronchodilating compositions and methods of use thereof | |
AU2002244211A1 (en) | Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEY, L.P., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BANERJEE, PARTHA S.;CHAUDRY, IMTIAZ A.;REEL/FRAME:012214/0107 Effective date: 20010710 |
|
AS | Assignment |
Owner name: DEY, L.P., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHAM, STEPHEN;REEL/FRAME:019585/0903 Effective date: 20070531 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT Free format text: SECURITY AGREEMENT;ASSIGNORS:MYLAN LABORATORIES INC.;DEY, L.P.;DEY, INC.;AND OTHERS;REEL/FRAME:020004/0404 Effective date: 20071002 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: DEY, INC. (F/K/A DEY LABORATORIES, INC.), NEW JERS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: DEY PHARMA, L.P. (F/K/A DEY L.P.), NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: MYLAN PHARMACEUTICALS, INC., WEST VIRGINIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: MYLAN BERTEK PHARMACEUTICALS INC., TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: MYLAN INC. (F/K/A MYLAN LABORATORIES INC.), PENNSY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: MYLAN TECHNOLOGIES, INC., VERMONT Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 Owner name: MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, IN Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:027261/0928 Effective date: 20111114 |